# Repeated recurrence after endovascular treatment for cerebral aneurysms: predictive clinical factors and optimal therapeutic management

**Authors:** Kota Kurisu, Hiroyuki Sakata, Yasushi Matsumoto, Atsushi Kanoke, Shunsuke Omodaka, Miki Fujimura, Hidenori Endo

PMC · DOI: 10.1007/s10143-025-03758-w · Neurosurgical Review · 2025-08-16

## TL;DR

This study identifies factors that predict recurring cerebral aneurysms after endovascular treatment and suggests repeat treatments are safe and effective.

## Contribution

The study identifies predictive factors for refractory aneurysms and evaluates the effectiveness of repeated endovascular treatments.

## Key findings

- Large aneurysm size and wall enhancement on imaging predict recurrence after treatment.
- Repeated endovascular treatments achieved good outcomes with low complication rates.
- Careful follow-up is recommended for patients with high-risk aneurysm features.

## Abstract

Despite significant advances in endovascular treatment (EVT) of cerebral aneurysms, post-treatment recurrence necessitating multiple retreatments remains a severe concern. Herein, we investigated the clinical characteristics of aneurysms necessitating multiple retreatments after EVT (refractory aneurysms: R-ANs) and explored appropriate management strategies. This retrospective cohort study enrolled 1,045 aneurysms initially treated with EVT between 2016 and 2022. R-ANs were defined as cases requiring two or more retreatment sessions due to repeated recurrence or regrowth. Clinical data were retrospectively reviewed, and predictive factors were identified. Furthermore, the treatments performed and clinical outcomes were investigated. Of 1,045 aneurysms, 101 (9.7%) exhibited recurrence or regrowth requiring retreatment. Among these, 23 aneurysms (2.2%) requiring two or more retreatment sessions, which were classified as R-ANs. As for the predictive factors of R-AN development, large size (> 10 mm), and circumferential aneurysmal wall enhancement on vessel wall imaging (VWI) were identified as relevant and independent predictive factors, with odds ratios of 3.92 (95% CI, 1.36– 11.62), 8.02 (95% CI, 2.02– 53.6), respectively. In terms of therapeutic outcomes, repeat EVT sessions provided favorable long-term clinical outcomes (aneurysm stabilization, 85.0%; favorable occlusion, 65.0%) and low periprocedural complication rates (2.6%). This study identified the relevant predictive factors for R-AN development, suggesting that careful follow-up is essential in patients with these factors. Furthermore, repeated EVT sessions appears to be a safe and efficient treatment strategy for such challenging cases.

## Full-text entities

- **Diseases:** thrombosis (MESH:D013927), hyperlipidemia (MESH:D006949), HS (MESH:C567159), ischemic (MESH:D002545), FD (MESH:D054318), oculomotor nerve palsy (MESH:D015840), visual field defects (MESH:D005128), visual disturbances (MESH:D014786), polycystic kidney disease (MESH:D007690), ischemic complications (MESH:D017202), hemorrhagic (MESH:D006470), Subarachnoid Aneurysm (MESH:D013345), EVT (MESH:D016609), R-AN (MESH:C580424), BA aneurysm (MESH:D002532), dyslipidemia (MESH:D050171), hypertension (MESH:D006973), mRS (MESH:C538175), inflammation (MESH:D007249), occlusion (MESH:D001157), Aneurysm (MESH:D000783), dissecting aneurysms (MESH:D000784), ruptured aneurysm (MESH:D017542), Rupture (MESH:D012421), stroke (MESH:D020521), R-ANs (MESH:D000069279)
- **Chemicals:** Antiplatelet (-), Gadolinium (MESH:D005682), aspirin (MESH:D001241), platinum (MESH:D010984), clopidogrel (MESH:D000077144)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12356742/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12356742/full.md

---
Source: https://tomesphere.com/paper/PMC12356742